Drugs in Clinical Pipeline: MCLA-117 | CLEC12AxCD3 Bispecific Immunoglobulin G (IgG) | Bispecific Antibody I Treatment for Acute Myleoid Leukemia (AML)

MCLA-117 is a full length human CLEC12AxCD3 bispecific immunoglobulin G (IgG) that incorporates CH₂ region amino acid substitutions to abrogate Fcγ receptor and C1q interactions while retaining its binding to FcRn. MCLA-117 binds to CD3, a cell-surface molecule present on all T cells, and CLEC12A, a cell surface molecule present on Acute Myleoid Leukemia (AML) cells and stem cells. MCLA-117 is designed to recruit and activate T-cells to kill CLEC12A-expressing AML tumor cells and stem cells, which may prevent recurrence of tumors. MCLA-117 redirects patient's cytotoxic T cells to induce AML tumor lysis.